A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy

Phase 1WithdrawnNCT02193672

M.D. Anderson Cancer Center

Overview

The goal of this clinical research study is to find out if using the tracer (liquid used in imaging scans) \[18F\]fluciclatide in positron emission tomography / computed tomography (PET/CT) scans will help researchers learn more quickly if the disease is responding to treatment.

PET/CT Scans: If you are found eligible to take part in this study, you will have a PET/CT scan at your treatment baseline visit, about 1 week before your first cycle of chemotherapy. You will then have a second PET/CT scan at the end of your first cycle of chemotherapy (about 3-4 weeks after starting chemotherapy). For up to 6 hours before the PET/CT scan, you must not eat or drink anything except water. A small needle and tube will be placed in your arm, and you will receive an injection of a very small amount of a mildly radioactive material into your bloodstream (the investigational tracer, \[18F\]fluciclatide). The radioactive nature of this injected material allows the scanner to "see" it in certain places in your body. After the injection, you will need to rest quietly until it is time for the scan. The amount of rest time may vary, but be prepared to wait for between 45 and 90 minutes. During the scan, you will lie flat on your back on a table. The scan itself may last up to 1 hour. Each PET/CT imaging session will last about 4 hours total from the time you arrive at the clinic until you are discharged and allowed to go home. You may be discharged 30 minutes after the scan is complete, if the doctor thinks you are clinically stable and it is safe for you to leave. Study Visits: If the following tests are already being performed as part of the clinical research study you are participating in or as part of standard care, they will not need to be repeated for this study. Baseline Visit (before the first PET/CT is performed): * You will have a physical exam. * Blood (about 3 tablespoons) will be drawn for routine tests. * If you can become pregnant, urine will be collected for a pregnancy test. To take part in this study, you must not be pregnant. End of Cycle 1 (before the second PET/CT is performed): -Blood (about 3 tablespoons) will be drawn for routine tests. About 24 hours after each PET/CT is performed, the study staff will call you by telephone to ask about your health status and any side effects you may be experiencing. Anytime within the next month after the second PET/CT scan, blood (about 3 tablespoons) will be drawn for routine tests. When your chemotherapy is over, you will have a third PET/CT scan as part of your standard care, and an FDG tracer will be used for that scan. Length of Participation: Your study participation will end about 6 weeks after your second PET/CT scan is performed. This is an investigational study. \[18F\]Fluciclatide is not FDA approved or commercially available. At this time, it is only being used in research. Up to 50 patients will take part in this research study. All will be enrolled at MD Anderson.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Conditions

Advanced Cancers

Interventions

[18F] FluciclatideDRUG

\[18F\] Fluciclatide given by vein before PET/CT scan.

PET/CT ScanPROCEDURE

PET/CT scan performed at treatment baseline visit, and about 1 week before first cycle of chemotherapy. Then, a PET/CT scan performed at end of first cycle of chemotherapy.

Phone CallsBEHAVIORAL

Phone call to participants by study staff about 24 hours after each PET/CT is performed.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patient is \>/= 18 years and male or female of any race/ethnicity. 2. Patient or patient's legally authorized representative provides written informed consent and is willing to comply with protocol requirements. 3. Patient must be scheduled to receive an anti-VEGF inhibitor (bevacizumab, sorafenib, sunitinib, other), mTOR inhibitor (temsirolimus, everolimus, other), or other molecules with antiangiogenic properties including taxol as anti-cancer therapy. 4. Patient must have normal hepatic and renal function defined as: 1) AST (SGOT)/ALT (SGPT) \</=3 x institutional upper limit of normal and 2) serum creatinine \</= 2x institutional upper limit of normal. 5. Platelet count of \> 75 x 10\^3/μL 6. Patients may participate in clinical trials in the Phase I program. 7. Patients with any solid tumor type. Exclusion Criteria: 1. Patient is not capable of complying with study procedures. 2. Female patient is pregnant or nursing; exclude the possibility of pregnancy by one of the following: 1) Confirming in medical history that the patient is postmenopausal defined as 12 consecutive months of amenorrhea, or surgically sterile, 2) Confirming the patient is using one of the following methods of birth control for a minimum of one month prior to entry into this study: Intrauterine device (IUD), oral contraceptives, Depo-Provera, or Norplant, 3) Confirming a negative urine dipstick test taken the morning of receiving the investigational agent \[18F\]fluciclatide.

Outcomes

Primary Outcomes

Change in Tumor Uptake

Primary efficacy endpoint is change in tumor uptake of investigational agent \[18F\]Fluciclatide, as measured by standardized uptake value (SUVFluciclatide) from before treatment to after one cycle of treatment but before the second cycle starts. This determined from investigational agent \[18F\]Fluciclatide PET scans. Changes in SUVFluciclatide compared to standard tumor's response measured after completion of 2 cycles of treatment as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) as well as tumor size change as a continuous variable measured by the standard CT or PET/CT scans. Tumor size can also be measured by the WHO two-dimensional measurement in addition to the Response Evaluation Criteria in Solid Tumors (RECIST), one-dimensional measurement. Changes in SUVFluciclatide after one cycle also compared to tumor volume and tumor size as continuous variables after two cycles.

Time frame: After 2, four week chemotherapy cycles

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.